<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556906</url>
  </required_header>
  <id_info>
    <org_study_id>UP1001</org_study_id>
    <nct_id>NCT01556906</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor</brief_title>
  <official_title>A Phase II Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Efficacy of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor BMS-201038 in Patients With Homozygous Familial Hypercholeterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Doris Duke Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of 4 doses of
      lomitapide (AEGR-733; BMS-201038) given as an initial low dose and then escalated through an
      additional 3 dose levels over a 16-week period.

      The secondary objectives of this study included the evaluation of the pharmacodynamics of
      lomitapide based on:

        -  Percent change in low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC),
           triglycerides, and very low density lipoprotein cholesterol (VLDL-C) concentrations at
           the end of each 4-week dosing period compared to the Baseline value of each parameter at
           the end of the previous dose phase(s).

        -  Changes in other plasma lipoproteins: apolipoproteins (apo B, apo AI, apo AII, apo CIII,
           apo E) and lipoprotein a [Lp(a)].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open-label, Phase 2 clinical trial designed to evaluate the safety,
      tolerability, and pharmacodynamics of lomitapide in the treatment of patients with homozygous
      familial hypercholesterolemia (HoFH).

      Patients are required to stop all lipid-lowering therapies, including apheresis, within 4
      weeks prior to the Baseline visit and throughout the study. Patients are placed on a rigorous
      low-fat diet (&lt;10% of energy from total dietary fat) at the Screening assessment; dietary
      counseling by a registered dietitian will be initiated at Screening and will continue at each
      subsequent study visit.

      Patients initially receive 0.03 mg/kg of lomitapide orally every day for 4 weeks.
      Intra-patient dose escalation to 0.1 mg/kg, 0.3 mg/kg/day and 1.0 mg/kg/day occur every 4
      weeks if specific protocol-defined stopping rules related to Grade 3 or 4 toxicities or
      serious adverse events (SAEs) do not apply.

      The study includes 15 study visits over 22 weeks: a Screening visit (Visit 1) conducted
      within 2 weeks prior to dosing, a Baseline visit (Visit 2) conducted on Day 1 prior to the
      first dose, 12 visits conducted during the treatment period (Visits 3 through 14), and a
      Follow-up visit (Visit 15) conducted approximately 4 weeks after the last dose of lomitapide.

      Screening and Baseline procedures include medical and medication history, physical
      examination, vital signs, 12-lead electrocardiogram (ECG), pulmonary function tests (PFTs),
      safety laboratory tests, fat soluble vitamin levels and a fatty acid profile. Nuclear
      magnetic resonance spectroscopy (NMRS) of the liver will be conducted at Baseline, at the end
      of each dosing period, and at the follow up visit to assess hepatic fat content. Baseline
      efficacy assessment includes a fasting lipid profile (TC, LDL-C [directly measured], VLDL-C,
      high density lipoprotein-cholesterol [HDL-C], triglycerides, and apolipoproteins [apo B, apo
      AI, apo AII, apo CIII, apo E] and Lp(a)).

      Safety and lipid profile assessments are repeated during the treatment period and at the
      Follow-up visit conducted 28 days after the last dose of lomitapide.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C</measure>
    <time_frame>Up to 16 weeks of treatment comapred to Baseline</time_frame>
    <description>Percent change in LDL-C compared to Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute change from Baseline in ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Aspartate Aminotransferase (AST)</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute change from Baseline in AST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Total Bilirubin</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute change from Baseline in total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Hepatic Fat Percent</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute change from Baseline in hepatic fat percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Forced Expiratory Volume During 1 Second (FEV1)</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute change from Baseline in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Carbon Monoxide Lung Diffusing Capacity (DLCO)(a Pulmonary Function Test)</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute change from Baseline in DLCO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Vitamin A</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute change from Baseline in vitamin A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Vitamin E</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute change from Baseline in vitamin E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Vitamin D</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute Change From Baseline in Vitamin D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Ratio of Vitamin E to Total Lipids</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute Change From Baseline in ratio of vitamin E to total lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Alpha Linoleic Acid (ALA)</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute Change From Baseline in ALA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Eicosapentaenoic Acid (EPA)</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute Change From Baseline in EPA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Docosahexaenoic Acid (DHA)</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute Change From Baseline in DHA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Linoleic Acid (LA)</measure>
    <time_frame>Baseline and 16 weeks of treatment</time_frame>
    <description>Absolute Change From Baseline in LA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Lomitapide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open label trial where all patients receive lomitapide (AEGR733/BMS-201038)at escalating doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomitapide</intervention_name>
    <description>Oral administration with escalating doses administered once daily</description>
    <arm_group_label>Lomitapide</arm_group_label>
    <other_name>AEGR-733</other_name>
    <other_name>BMS-201038</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females ≥13 years of age

          2. Clinical diagnosis of HoFH AND one of the following (a, b, or c):

               -  Documented functional mutation in both LDL receptor alleles, OR

               -  Skin fibroblast LDL receptor activity &lt;20% of normal, OR

               -  TC &gt;500 mg/dL AND triglycerides &lt; 300 mg/dL AND both parents with documented TC
                  &gt;250 mg/dL

          3. Body weight ≥40 kg

          4. Negative screening pregnancy test if female of child-bearing potential

          5. Subjects must be willing and able to comply with all study-related procedures

          6. Subjects must be willing and able to go off all lipid-lowering medications, dietary
             supplements (psyllium preparations) and LDL apheresis within 4 weeks prior to the
             Baseline visit until the end of the study.

        Exclusion Criteria:

          1. Uncontrolled hypertension defined as: systolic blood pressure &gt;180 mmHg, diastolic
             blood pressure &gt;95 mmHg

          2. History of chronic renal insufficiency (serum creatinine &gt;2.5 mg/dL)

          3. History of liver disease or abnormal LFTs at screening (&gt;3x upper limit of normal
             [ULN])

          4. Any major surgical procedure occurring &lt; 3 months prior to the screening visit

          5. Cardiac insufficiency defined by the New York Heart Association classification as
             functional Class III or Class IV

          6. History of a non-skin malignancy within the previous 5 years

          7. History of alcohol or drug abuse

          8. Participation in an investigational drug study within 6 weeks prior to the screening
             visit

          9. Serious or unstable medical or psychological conditions that, in the opinion of the
             Investigator, would compromise the patient's safety or successful participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan J Rader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007 Jan 11;356(2):148-56.</citation>
    <PMID>17215532</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2012</study_first_posted>
  <results_first_submitted>January 18, 2013</results_first_submitted>
  <results_first_submitted_qc>January 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2013</results_first_posted>
  <last_update_submitted>April 4, 2013</last_update_submitted>
  <last_update_submitted_qc>April 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was performed from 05 Jun 2003 to 16 Feb 2004. The study was performed at a single medical clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lomitapide Escalated</title>
          <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lomitapide Escalated</title>
          <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>LDL-C</title>
        <description>Percent change in LDL-C compared to Baseline.</description>
        <time_frame>Up to 16 weeks of treatment comapred to Baseline</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-C</title>
          <description>Percent change in LDL-C compared to Baseline.</description>
          <population>All patients treated</population>
          <units>percentage change in LDL-C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.94" spread="9.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Alanine Aminotransferase (ALT)</title>
        <description>Absolute change from Baseline in ALT</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Alanine Aminotransferase (ALT)</title>
          <description>Absolute change from Baseline in ALT</description>
          <population>All patients treated</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" spread="85.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Aspartate Aminotransferase (AST)</title>
        <description>Absolute change from Baseline in AST</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Aspartate Aminotransferase (AST)</title>
          <description>Absolute change from Baseline in AST</description>
          <population>All patients treated</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="32.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Total Bilirubin</title>
        <description>Absolute change from Baseline in total bilirubin</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Total Bilirubin</title>
          <description>Absolute change from Baseline in total bilirubin</description>
          <population>All patients treated</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Hepatic Fat Percent</title>
        <description>Absolute change from Baseline in hepatic fat percent</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Hepatic Fat Percent</title>
          <description>Absolute change from Baseline in hepatic fat percent</description>
          <population>All patients treated</population>
          <units>percent of hapatic fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Forced Expiratory Volume During 1 Second (FEV1)</title>
        <description>Absolute change from Baseline in FEV1</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Forced Expiratory Volume During 1 Second (FEV1)</title>
          <description>Absolute change from Baseline in FEV1</description>
          <population>All patients treated</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.070" spread="0.2406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Carbon Monoxide Lung Diffusing Capacity (DLCO)(a Pulmonary Function Test)</title>
        <description>Absolute change from Baseline in DLCO</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Carbon Monoxide Lung Diffusing Capacity (DLCO)(a Pulmonary Function Test)</title>
          <description>Absolute change from Baseline in DLCO</description>
          <population>All patients treated</population>
          <units>mL CO/min/mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.020" spread="5.3246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Vitamin A</title>
        <description>Absolute change from Baseline in vitamin A</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Vitamin A</title>
          <description>Absolute change from Baseline in vitamin A</description>
          <population>All patients treated</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Vitamin E</title>
        <description>Absolute change from Baseline in vitamin E</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Vitamin E</title>
          <description>Absolute change from Baseline in vitamin E</description>
          <population>All patients treated</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-94.35" spread="130.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Vitamin D</title>
        <description>Absolute Change From Baseline in Vitamin D</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Vitamin D</title>
          <description>Absolute Change From Baseline in Vitamin D</description>
          <population>All patients treated</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.57" spread="10.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Ratio of Vitamin E to Total Lipids</title>
        <description>Absolute Change From Baseline in ratio of vitamin E to total lipids</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Ratio of Vitamin E to Total Lipids</title>
          <description>Absolute Change From Baseline in ratio of vitamin E to total lipids</description>
          <population>All patients treated</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Alpha Linoleic Acid (ALA)</title>
        <description>Absolute Change From Baseline in ALA</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Alpha Linoleic Acid (ALA)</title>
          <description>Absolute Change From Baseline in ALA</description>
          <population>All patients treated</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Eicosapentaenoic Acid (EPA)</title>
        <description>Absolute Change From Baseline in EPA</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Eicosapentaenoic Acid (EPA)</title>
          <description>Absolute Change From Baseline in EPA</description>
          <population>All patients treated</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Docosahexaenoic Acid (DHA)</title>
        <description>Absolute Change From Baseline in DHA</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Docosahexaenoic Acid (DHA)</title>
          <description>Absolute Change From Baseline in DHA</description>
          <population>All patients treated</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Linoleic Acid (LA)</title>
        <description>Absolute Change From Baseline in LA</description>
        <time_frame>Baseline and 16 weeks of treatment</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Escalated</title>
            <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Linoleic Acid (LA)</title>
          <description>Absolute Change From Baseline in LA</description>
          <population>All patients treated</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose through 28 days post-treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lomitapide Escalated</title>
          <description>Lomitapide initiated with an oral dose of 0.03 mg/kg/day for 4 weeks and then escalated through an additional 3 dose levels (0.1, 0.3, and 1.0 mg/kg/day) every 4 weeks over a 16-week period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alinine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>International normalized ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Xanthoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Information is unavailable.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Aegerion Pharmaceutical</organization>
      <phone>617-500-7867</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

